ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2074

Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients

Sergio Maldonado Chaar1 and Kelly Corbitt2, 1University of Miami/Jackson Health, Miami, FL, 2University of Miami Miller School of Medicine, El Portal, FL

Meeting: ACR Convergence 2025

Keywords: Cohort Study, dermatomyositis, interstitial lung disease, Minority Health, Mortality

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2052–2078) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Anti-melanoma differentiation-associated protein 5 (MDA-5) antibody positivity in dermatomyositis (DM) is often associated with development of interstitial lung disease (ILD), with factors such as advanced age, male sex, lymphopenia, elevated ferritin and elevated lactate dehydrogenase (LDH) increasing mortality risk. Limited studies exist evaluating these risk factors in Hispanic patients. This retrospective study aims to evaluate these risk factors in a predominantly Hispanic population.

Methods: A retrospective cohort analysis was performed using electronic medical record data from 2021 to 2024 including all adult patients with a diagnosis code of either ILD and an abnormal myositis panel or DM. A total of 184 medical record numbers (MRNs) met these criteria. After confirming clinical diagnosis and filtering for positive anti-MDA5-antibodies, 17 MRNs were included. Lymphopenia was defined as an absolute lymphocyte count (ALC) less than 1000 cells/microliter. Advanced age was defined as 50 years or older. Data was analyzed using fisher exact testing.

Results: 29.4% (n=5) of patients were male and 70.6% (n=12) were female with a median age of 58 years. 76.0% (n=13) were Hispanic, including all males and 8 females. 7 patients (41.2%) had amyopathic DM, 4 (23.5%) had DM, and 6 (35.3%) had ILD without inflammatory myositis. 76.5% (n=13) of patients had ILD, including all of the males and 8 females. 23.5% (n=4) of patients were deceased, all of whom were males with ILD. Of 12 patients with advanced age, 25% (n=3) were deceased and 83.3% (n=10) had ILD. 9 patients had available LDH levels. Of these, five patients had elevated LDH and 4 were deceased. 8 patients had available ferritin levels, all of which were elevated. Of those patients, 88.5% (n=7; 3 males and 4 females) had ILD, and 37.5 % (n=3) were deceased. Lymphopenia was found in 35.3% (n=6; 4 males and 2 females). Mean ALC was 564 cells/microliter. Of these patients, 83.0% (n=5; 4 males and 1 female) had ILD and 66.7% (n=4) were deceased. A Fisher-exact-test showed significant associations between deceased and lymphopenia (p=0.006), males and lymphopenia (p=0.028), and males and deceased (p=0.002). There was no significant association of advanced age, elevated LDH level, and ILD with increased mortality. Elevated ferritin was not included in this analysis as all those tested had elevated levels.

Conclusion: Our cohort suggests a possible increased risk of mortality in anti-MDA5 antibody positive ILD patients who are male and have lymphopenia. We looked at a largely Hispanic population, which is underrepresented in anti-MDA5 antibody literature. Due to the limited sample size, larger cohorts should be examined to see if this association remains.

Supporting image 1Table 1: Comparison between males and females based on various classification groups.


Disclosures: S. Maldonado Chaar: None; K. Corbitt: None.

To cite this abstract in AMA style:

Maldonado Chaar S, Corbitt K. Increased Mortality in Hispanic Males with Lymphopenia: A Descriptive and Statistical Analysis of Anti-Melanoma Differentiation-Associated Protein 5 (MDA-5) Antibody Positive Patients [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/increased-mortality-in-hispanic-males-with-lymphopenia-a-descriptive-and-statistical-analysis-of-anti-melanoma-differentiation-associated-protein-5-mda-5-antibody-positive-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/increased-mortality-in-hispanic-males-with-lymphopenia-a-descriptive-and-statistical-analysis-of-anti-melanoma-differentiation-associated-protein-5-mda-5-antibody-positive-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology